These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE. BMJ Open; 2019 May 14; 9(5):e026779. PubMed ID: 31092657 [Abstract] [Full Text] [Related]
24. A novel nomogram for peritoneal mesothelioma predicts survival. Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I. Ann Surg Oncol; 2013 Feb 14; 20(2):555-61. PubMed ID: 23233234 [Abstract] [Full Text] [Related]
27. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis. Vassos N, Förtsch T, Aladashvili A, Hohenberger W, Croner RS. World J Surg Oncol; 2016 Feb 24; 14(1):42. PubMed ID: 26912149 [Abstract] [Full Text] [Related]
28. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Hommell-Fontaine J, Isaac S, Passot G, Decullier E, Traverse-Glehen A, Cotte E, You B, Mohamed F, Gilly FN, Glehen O, Berger F. Ann Surg Oncol; 2013 Nov 24; 20(12):3892-8. PubMed ID: 23800898 [Abstract] [Full Text] [Related]
29. Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for children, adolescents, and young adults: the first 50 cases. Hayes-Jordan A, Green H, Lin H, Owusu-Agyemang P, Mejia R, Okhuysen-Cawley R, Cortes J, Fitzgerald NE, McAleer MF, Herzog C, Huh WW, Anderson P. Ann Surg Oncol; 2015 May 24; 22(5):1726-32. PubMed ID: 25564159 [Abstract] [Full Text] [Related]
31. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center. Berger Y, Aycart S, Mandeli JP, Heskel M, Sarpel U, Labow DM. Surg Oncol; 2015 Sep 24; 24(3):264-9. PubMed ID: 26143715 [Abstract] [Full Text] [Related]
32. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Acs M, Gerken M, Gajic I, Mayr M, Zustin J, Piso P. Langenbecks Arch Surg; 2022 Nov 24; 407(7):3057-3067. PubMed ID: 35732846 [Abstract] [Full Text] [Related]
33. Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma. Ali YM, Sweeney J, Shen P, Votanopoulos KI, McQuellon R, Duckworth K, Perry KC, Russell G, Levine EA. Ann Surg Oncol; 2020 Jan 24; 27(1):117-123. PubMed ID: 31069554 [Abstract] [Full Text] [Related]
34. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases. Choudry HA, Bednar F, Shuai Y, Jones HL, Pai RK, Pingpank JF, Ahrendt SS, Holtzman MP, Zeh HJ, Bartlett DL. Ann Surg Oncol; 2019 May 24; 26(5):1445-1453. PubMed ID: 30825033 [Abstract] [Full Text] [Related]
38. Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread: A French nationwide study over 14 years. Scalabre A, Philippe-Chomette P, Passot G, Orbach D, Elias D, Corradini N, Brugières L, Msika S, Leclair MD, Joseph S, Brigand C, Becmeur F, Soler C, Pezet D, Gagniere J, Glehen O, Sarnacki S. Pediatr Blood Cancer; 2018 Apr 24; 65(4):. PubMed ID: 29286576 [Abstract] [Full Text] [Related]